COMMUNIQUÉS West-GlobeNewswire

The Ferrari Foundation Advances Fifth Annual Adam Ferrari Health Science Scholarship to Finalist Review
03/08/2026
Three finalists will be selected for the $20,000 scholarship before the recipient is announced on September 1 IRVINE, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- The Ferrari Foundation has begun the finalist selection [...]
Felix Ankel, MD, Elected President of ABEM
03/08/2026
American Board of Emergency Medicine Announces 2026-2027 Executive Committee EAST LANSING, Mich., Aug. 03, 2026 (GLOBE NEWSWIRE) -- The American Board of Emergency Medicine (ABEM) announces the election of Felix Ankel, [...]
Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance
03/08/2026
WILMINGTON, Del., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that it expects to issue 172,058 shares of its common stock to GPCR Therapeutics, Inc. (“GPCR [...]
SBC Medical to Announce 2Q 2026 Financial Results
03/08/2026
IRVINE, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization providing management support across a wide range [...]
Vaso Corporation Completes Sale of NetWolves Network Services to COEO Solutions
03/08/2026
Vaso Corporation 137 Commercial Street Plainview, New York 11803 Tel: (516) 997-4600 Fax: (516) 997-2299 Investor Contact: Jonathan Newton Investor Relations Phone: 516-997-4600 Email: jnewton@vasocorporation.com [...]
Helus Pharma Appoints Michael Halstead as Chief Executive Officer
03/08/2026
Former President of Intra-Cellular Therapies, Inc. was instrumental in building and scaling the company, which was subsequently acquired by Johnson & Johnson Experienced executive with a proven track record of [...]
Curium Announces Definitive Agreement to Merge with Lantheus
03/08/2026
Strategic transaction would bring Curium's theranostics portfolio and global manufacturing platform together with Lantheus’ complementary U.S. radiodiagnostics business Total transaction consideration to Lantheus [...]
ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial Results
03/08/2026
SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic [...]
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/08/2026
CLEVELAND, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in [...]
Crescent Biopharma Announces Grants of Inducement Awards
03/08/2026
WALTHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma , Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies [...]
Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom
03/08/2026
Dr. Mehmud’s appointment further aligns the scientific, clinical, regulatory and operational leadership of Antev PHILADELPHIA, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “ [...]
Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC)
03/08/2026
Longitudinal study includes first published real-world data on arimoclomol in adults with NPC and provides insights across a broad patient population BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. ( [...]
BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET
03/08/2026
PALO ALTO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today [...]
Veritasium Goes Behind the Scenes at Kraig Biocraft Laboratories to Explore the Future of Commercial Spider Silk
03/08/2026
What happens when one of the world's most influential science channels spends the day exploring one of nature's most extraordinary materials? The answer is Veritasium's latest spider silk episode. From molecular biology [...]
Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health
03/08/2026
Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026 BOTHELL, Wash., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal [...]
Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results
03/08/2026
$119.2 million in 2Q VYJUVEK global revenue and $965.9 million since launch Multiple clinical data readouts in 2H 2026 On track for VYJUVEK launches in Spain and Italy later this year Strong balance sheet, ending the [...]
Ceribell Secures CMS New Technology Add-On Payment (NTAP) for Breakthrough Point-of-Care Delirium Monitor System
03/08/2026
Incremental NTAP Reimbursement Stands to Broaden Access to First-of-Its-Kind Dual Seizure and Delirium Monitoring Platform SUNNYVALE, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell” [...]
Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia
03/08/2026
First-in-class pan-RAS(ON) ADC is cleared for clinical development Designed to selectively deliver pan-RAS(ON) inhibition to tumors while minimizing systemic toxicity. IND submissions to U.S. FDA and China NMPA are in [...]
Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights
03/08/2026
Ocular’s AXPAXLI TM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026 FDA Type C Meeting Minutes Formalize SOL-1 Trial with Confirmatory Evidence as Sufficient [...]

Pages